Saturday 17 October 2026 Export TOVX’s income statement to Excel — free account

Theriva Biologics, Inc.

In the quarter to June 2026, EPS grew 96.4%, free cash flow grew 34.7% and total debt fell 1.16%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

0.21 0.00 0.00%

Follow TOVX

Alert me

Market cap: $9.7M
P/E: 0.1×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 1.64%

Capital & Financial Ratios $m

Market Cap 9.73

Revenue 2.61

Net Income (11.62)

Free Cash Flow (12.78)

Net Debt (9.72)

Current Ratio 1.13

Debt/Equity 0.13

P/E ratio 0.15

Fwd P/E —

P/S ratio 0.00

P/B ratio 0.79

Past 5Y EPS Growth —

This Y EPS Growth 87.74%

Next Y EPS Growth 15.69%

Next Y revenue growth —

Next 5Y EPS Growth 46.42%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

P/B against its own 10 years 65.07%

10-year low 10-year high

EV/FCF against its own 10 years 0.47%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	23	12	13	11
Receivables	2	3	3	2
Inventory	—	—	—	—
Other	—	—	—	—
	27	16	17	14

	2023	2024	2025	Q'26
Payables	1	1	1	1
ST’ Debt	—	—	—	—
Other	—	—	—	3
	7	8	10	12

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.25%	0.00%	(33.30%)

Revenue $m

	Year

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(2)	(3)	—	—	—
’25	(5)	(5)	(4)	(3)	(17)
’24	(5)	(3)	(4)	(5)	(17)
’23	(6)	(4)	(3)	(7)	(19)
’22	(5)	(4)	(4)	(5)	(19)
’21	(3)	(3)	(2)	(5)	(13)
’20	(5)	(2)	(2)	(3)	(12)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(2)	(3)	—	—	—
’25	(5)	(5)	(4)	(3)	(17)
’24	(5)	(3)	(4)	(5)	(17)
’23	(6)	(4)	(3)	(7)	(19)
’22	(5)	(4)	(4)	(5)	(19)
’21	(3)	(3)	(2)	(5)	(13)
’20	(5)	(2)	(2)	(3)	(12)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.05)	(0.07)	—	—	—
’25	(1.55)	(1.93)	(0.45)	1.98	(2.08)
’24	(7.50)	(10.75)	(6.81)	6.03	(19.03)
’23	(7.50)	(8.50)	(4.75)	(8.00)	(28.50)
’22	(7.50)	(7.75)	(8.25)	(9.00)	(32.75)
’21	(32.50)	(5.00)	(5.00)	(10.00)	(47.50)
’20	(50.00)	(45.00)	(35.00)	(35.00)	(165.00)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	6,387.50	3,587.50	127.50	92.50	62.50	65.00	9.75	5.00	1.14	0.17	Analyst estimates 2026–2028 Powerpack
	High	23,975.00	9,187.50	5,250.00	212.50	187.50	425.00	110.00	31.50	17.00	2.03
People
People	Employees	30	25	13	11	10	9	9	22	22	16
	Revenue/emp, $m	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	—	—
	Gross margin, %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—
	EBT	(28)	(15)	(13)	(15)	(10)	(14)	(21)	(20)	(26)	(24)
	EBT margin, %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Net income	(28)	(15)	(13)	(15)	(10)	(14)	(20)	(18)	(26)	(24)
	Depreciation	0	0	0	0	0	0	0	0	6	0
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Earnings	(2,534.96)	(1,573.43)	(1,015.00)	(245.00)	(165.00)	(47.50)	(32.75)	(28.50)	(19.03)	(2.08)
	Cash flow	(2,583.43)	(1,422.82)	(693.94)	(210.84)	(160.11)	(26.44)	(31.12)	(29.48)	(12.56)	(1.37)
	Capex	(52.69)	(14.93)	(0.28)	0.00	(0.12)	(0.03)	(0.19)	(0.31)	0.00	0.00
	Free cash flow	(2,636.11)	(1,437.75)	(694.22)	(210.84)	(160.22)	(26.47)	(31.31)	(29.80)	(12.56)	(1.38)
	Book value	208.24	(240.14)	568.63	(16.06)	(99.21)	134.17	84.54	57.37	14.14	1.27
	Shares, m	0	0	0	0	0	0	1	1	1	12
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	—	—
	P/S	—	—	—	—	—	—	—	—	—	—
	P/B	—	—	—	—	—	—	—	—	—	—
	EV/Sales	—	—	—	—	—	—	—	—	—	—
	EV/FCF	—	—	—	—	—	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	(28)	(20)	(17)	(14)	(12)	(13)	(19)	(19)	(17)	(17)
	Capex	(1)	0	0	—	0	0	0	0	0	0
	Free cash flow	(28)	(20)	(17)	(14)	(12)	(13)	(19)	(19)	(17)	(17)
Balance, $m
Balance, $m	Working capital	2	8	26	11	5	65	38	21	9	7
	Total debt	—	—	—	0	0	1	0	0	0	2
	Net debt	(19)	(17)	(29)	(15)	(6)	(66)	(42)	(23)	(12)	(11)
	Shareholders’ equity	2	(3)	14	(1)	(8)	65	52	37	19	15
Returns, %
Returns, %	ROA	(102.19)	(107.10)	(103.27)	(67.87)	(97.93)	(58.87)	(28.16)	(28.88)	(56.65)	(68.62)
	ROIC	0.00	0.00	0.00	0.00	0.00	0.00	(131.40)	(96.03)	(218.10)	(375.98)
	ROE	(315.96)	3,813.26	(1,013.87)	(1,245.72)	158.60	(83.73)	(34.16)	(41.33)	(91.57)	(146.58)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2010 · latest quarter Mar 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
GDTC CytoMed Therapeutics Limited	$10.3M	— (loss-making)	— (loss-making)	—	n/m	−27.39% (below 0%: shrinking)	0.00%	—	Compare
BLRX BioLineRx Ltd.	$10.2M	— (loss-making)	— (loss-making)	−3.29% (below 0%: shrinking)	n/m	−1,827.71% (below 0%: shrinking)	79.93%	(1,215.31%)	Compare
LTRN Lantern Pharma Inc.	$10.0M	— (loss-making)	—	—	n/m	+25.31% (above 0%: growing)	0.00%	0.00%	Compare
TOVX Theriva Biologics, Inc.	$9.7M	0.1×	—	+33.08% (above 0%: growing)	n/m	+34.69% (above 0%: growing)	100.00%	0.00%
BIVI BioVie Inc.	$9.6M	— (loss-making)	—	—	n/m	+26.50% (above 0%: growing)	0.00%	0.00%	Compare
LSTA Lisata Therapeutics, Inc.	$9.6M	— (loss-making)	— (loss-making)	−98.30% (below 0%: shrinking)	n/m	+33.04% (above 0%: growing)	100.00%	0.00%	Compare
VTGN VistaGen Therapeutics, Inc.	$9.5M	— (loss-making)	— (loss-making)	+504.92% (above 0%: growing)	n/m	+22.23% (above 0%: growing)	100.00%	(904.34%)	Compare
CMMB Chemomab Therapeutics Ltd. Sponsored ADR	$9.4M	— (loss-making)	—	—	n/m	+47.89% (above 0%: growing)	0.00%	0.00%	Compare
MTVA MetaVia Inc.	$9.0M	— (loss-making)	—	—	n/m	−22.42% (below 0%: shrinking)	—	0.00%	Compare
Median of peers	$9.6M	—	—	−3.29%	—	+23.77%	0.00%	0.00%

All 614 Biotechnology stocks →

Theriva Biologics, Inc. (TOVX) key facts

Theriva Biologics, Inc. (TOVX) is a Biotechnology company in the Healthcare sector, listed on NYSE American.
As of October 16, 2026, TOVX traded at $0.21, a market capitalization of $9.7 million.
Return on equity was −146.6% and debt-to-equity 0.13.

Source: company filings (standardised) and stockrow calculations.